SynthesisBMC cancer2025
Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLysophosphatidic acid receptor 1 (LPAR1) mediates various biological behaviors in physiological and pathological processes. This study aims to comprehensively evaluate the prognostic value of LPAR1 expression and methylation in LGG, and explore their functional effects on tumor progression and immune regulation.
methodsThe GEO database was used to analyze LPAR1 expression in tumors and normal tissues. The TCGA-LGG and CGGA datasets were used to analyze the expression, methylation, immunity and prognostic significance of LGG. Immune cells and immune pathways were detected by flow cytometry, ELISA and western blot analysis. The role of LPAR1 in LGG was validated by RT-PCR, TUNEL assay, CCK-8 assay, flow cytometry, wound healing assay and transwell assay.
resultsWe included 627 patients who contained complete information required for analysis in the TCGA-LGG and CGGA datasets. Methylation of the LPAR1 promoter suppresses its expression. High methylation levels were associated with better overall survival (OS) and progression-free survival (PFS) (P < 0.05) in LGG. Decreased LPAR1 expression and increased methylation levels were significantly associated with age, histological types and isocitrate dehydrogenase (IDH) mutation status (P < 0.05). Multivariate analysis showed that LPAR1 was an independent prognostic factor for LGG (P = 0.002). Meta-analysis showed that high LPAR1 expression was indeed a poor prognosis for patients' OS in LGG (HR, 1.06; 95% CI, 0.95-1.17). Low LPAR1 expression affected the proportion of tumor immune infiltrating cells (TIICs) in the tumor microenvironment (TME), which was related to the involvement of LPAR1 in pathways such as CSK and Th1/Th2. In the cell experiment, LPAR1 overexpression promoted proliferation, migration, and invasion and inhibited apoptosis, whereas LPAR1 knockdown exhibited the opposite effect.
conclusionsLow LPAR1 expression or high LPAR1 methylation level was a potential prognostic molecular marker for favorable survival in LGG. Moreover, we identified a regulatory pattern in which a high level of LPAR1 methylation resulted in a decrease in LPAR1 expression, which affected the proportion of TIICs in TME. This pattern may work through CSK and Th1/Th2 pathways. Inhibiting LPAR1 can suppress the biological behavior of glioma cells in vitro. These findings open up new avenues for therapeutic and prognostic evaluation of LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.